コメントを投稿するにはログインが必要です
ログインページへ記事ができると、章ごとの要約と、聴きどころへ飛べる目次がここに並びます。いまは音声で聴けます。
#6-16E. Redefining Knee Osteoarthritis: Emerging Symptomatic and Disease-Modifying Therapies (Nat Rev Rheumatol, 2026)
2026年11月4日 13:00·5分46秒
Are we on the verge of a paradigm shift in managing knee osteoarthritis beyond simple analgesics? A comprehensive review highlights how understanding knee osteoarthritis as a complex whole-joint disease has accelerated emerging therapies, most notably incretin-based GLP-1 receptor agonists like semaglutide demonstrating substantial pain and functional improvements in obesity-associated cases. However, as a narrative review synthesizing preliminary phase II and III trials, many candidate disease-modifying drugs still lack definitive long-term structural efficacy and safety data. For clinicians, recognizing these mechanism-based targets enables a transition toward personalized, phenotype-driven patient care.
Citation: Alice Courties, Tobias Winkler, Philip G. Conaghan, Francis Berenbaum. Emerging therapies for knee osteoarthritis. Nature Reviews Rheumatology. 2026.
DOI: 10.1038/s41584-026-01441-y
Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.
